{"id":495435,"date":"2024-01-25T10:59:00","date_gmt":"2024-01-25T15:59:00","guid":{"rendered":"https:\/\/platohealth.ai\/benevolentai-appoints-former-bayer-rd-chief-as-ceo\/"},"modified":"2024-01-25T12:01:45","modified_gmt":"2024-01-25T17:01:45","slug":"benevolentai-appoints-former-bayer-rd-chief-as-ceo","status":"publish","type":"post","link":"https:\/\/platohealth.ai\/benevolentai-appoints-former-bayer-rd-chief-as-ceo\/","title":{"rendered":"BenevolentAI appoints former Bayer R&D chief as CEO","gt_translate_keys":[{"key":"rendered","format":"text"}]},"content":{"rendered":"
<\/div>\n

After a rocky year that featured a restructuring, job cuts<\/a> and the resignation of its CFO, BenevolentAI is looking to the future by tapping a Bayer veteran as its new CEO.<\/p>\n

Joerg Moeller, most recently the research and development chief at Leo Pharma, spent about 20 years at Bayer earlier in his career<\/a>, finishing his tenure as head of global research and development with a spot on the pharmaceuticals executive committee. He moved to Leo in early 2021, where he reorganized the R&D department in an effort to spur growth.<\/p>\n

A medical doctor by training, Moeller is an advocate of using artificial intelligence to speed drug discovery, BenevolentAI said Wednesday<\/a>. He\u2019s also initiated several collaborations with AI companies in his career and worked on deals to out-license assets. <\/p>\n

BenevolentAI is counting on that experience as it seeks more partners<\/a> in the pharmaceutical industry and explores licensing agreements for its own assets. Moeller is \u201ca well-known and respected figure within the target stakeholders of BenevolentAI,\u201d the company said. <\/p>\n

AI companies in general are working to convince investors that their technology is essential<\/a> to the future of drug discovery. Although BenevolentAI counts major drugmakers AstraZeneca, Eli Lilly and Merck KGaA<\/a> among its partners and has a number of experimental therapies in its pipeline<\/a>, the company has lost most of its value since going public in 2021<\/a>. <\/p>\n

Moeller will also serve as an executive board member, the London-based company said. Francois Nader<\/a>, who had been serving as acting CEO, will revert back to his post as non-executive chair.<\/p>\n